PR in the Philippines

HONG KONG, Aug 31, 2024 - (ACN Newswire via SeaPRwire.com) - GF Securities Co., Ltd. ("GF Securities" or the "Company", together with its subsidiaries within the scope of its consolidated financial statements (“subsidiaries”), the “Group”; HKSE: 1776; SZSE: 000776) announced its interim results for the six months ended 30 August 2024 (the “Reporting Period”). During the Reporting Period, under the guidance of the Board of Directors, the management of the Company led all staff to carry out key work to focus on enhancing core business capabilities, cultivating new quality competitiveness, improving comprehensive service capabilities and boosting resource allocation efficiency, as a result of which, the Company’s operating results achieved stable development with a total revenue and other income of RMB17,136  million, and a net profit attributable to owners of the Company of RMB4,362 million. As of 30 June, 2024, the Group’s total asset amounted to RMB689,328 million, representing an increase of 1.05 % as compared to the end of 2023 ; and equity attributable to owners of the Company amounted to RMB140,703 million, representing an increase of 3.67% as compared to the end of 2023.As one of the first batch of pilot comprehensive management brokerages selected by the CSRC, GF Securities possesses licenses for a full range of services involved in four business segments, including investment banking, wealth management, trading and institution, and investment management. The Group has successively set up futures subsidiaries, public fund subsidiaries, private fund subsidiaries, alternative investment subsidiaries and asset management subsidiaries. With its unique value concept and pragmatic entrepreneurial style, the Company has built up a full-service chain with comprehensive layout and strong strength. In respect  of regional development, the Company based in Guangdong and serves the whole country, connecting domestically and internationally, forges a leading national brokerage with a long-term vision and an open mind. Against this backdrop, the Company has maintained main operating indicators ranking among the top securities companies in China for many consecutive years, and established its leading advantages in various key business segments.Wealth Management Business Continues to Lead under Ongoing and Deepening TransformationThe Company has taken the lead in proposing wealth management transformation and has currently been equipped with excellent financial product research, sales capabilities and professional asset allocation capabilities. The Company had more than 4,400 securities investment advisors, ranking No. 1 in the industry (in terms of parent company caliber), striving to provide precise wealth management services to different clients.In the first half of 2024, the Company focused on strengthening the construction of investment research and professional investment & advisory service capabilities, continuing to build a differentiated product and service supply system, and promote the transformation of wealth management business into an investor-oriented buy-side investment advisory business to enhance investors’ sense of gain. In the domestic market, as of the end of June 2024, the total balance of financial products sold by the Company on a commission basis exceeded RMB220 billion, representing an increase of 4.00% as compared to the end of last year while the sales amount of financial products on the Yitaojin E-commerce platform (including Cash Return  and Taojin Market  amounted to RMB116.918 billion. In the overseas market, the Group further diversified its product offerings and continued to transform into wealth management with net sales income and balance of financial products and commissions for multi-market transactions achieving a year-on-year growth. In addition, the market share (in terms of trading volume and trading amount of futures) of GF Futures, the wholly-owned subsidiary of the Group, achieved year-on-year growth. GF Futures (Hong Kong) was awarded the Most Active Chinese Commodity Futures Broker of 2023 by the Singapore Exchange.At the end of June 2024, the Company had 356 branches and business departments nationwide, with a presence in 31 provinces, municipalities, and autonomous regions across the PRC. The number and coverage ratio of business outlets in the nine cities of the Pearl River Delta in the Guangdong-Hong Kong-Macao Greater Bay Area ranked No. 1 in the industry, providing a wide range of market reach for the Company’s business and laying important support for customer accumulation and service.Continuous Development of Insitutional Business with Outstanding Research Capabilies EmpowermentThe Company actively seizes the opportunities of reform on the investment, financing and trading, gives full play to the role of research in empowering and promoting the Company's core business, integrates resources to provide comprehensive solutions for institutional customers, improves institutional customer service capabilities and institutional customer service systems, and continues to expand institutional business.In the first half of 2024, the market-making business of the Company continued to be in the first echelon of the market, providing market-making services for more than 700 funds and all ETF options of the SSE and SZSE, and market-making services for CSI 300 stock index options and CSI 1000 stock index options of the China Financial Futures Exchange. The Company issued 44,559 private equity products through the China Securities Inter-agency Quotation System and OTC market, with a total amount of RMB338.330 billion. The Company became the lead market maker for stock index options of the China Financial Futures Exchange, and was granted the SSE’s 2023 Stock Option Market Development Contribution Award (Outstanding Option Market Maker Award and Contribution to New Option Varieties Award), the SZSE’s 2023 Outstanding ETF Liquidity Provider Award and Outstanding Option Market Maker Award, and the CFFEX’s 2023 Outstanding Stock Index Option Market Maker Award (Bronze Award). As the end of June 2024, the Company provided market-making services to 47 NEEQ enterprises while its bond market-making business created the “GF Securities Pearl River Delta ESG Sustainable Development Local Debt Basket ” to help market institutions actively participate in the green economy construction and sustainable development in the Pearl River Delta through portfolio investment.At the same time, as a primary dealer of OTC derivatives business with professional advantages in derivatives pricing and trading, the Company continued to strengthen the construction of team and system, enhanced product creation, strategy innovation and trading and sales capabilities, and diversified and expanded its product system, types of underlying products and revenue structure, so as to continuously provide institutional customers with asset allocation and risk management solutions through OTC derivatives.The Group continued to promote the research-driven business model and gave full play to the empowerment and promotion effect of research on the Company’s core business. As of the end of June 2024, the Group’s equity research covered 28 industries and 993 A-share listed companies in mainland China, and 154 Hong Kong and overseas listed companies. The Company achieved research results based on digital means such as GF research portal and mini programs, continued to explore in the direction of intelligence, and strived to build a multiplatform, multi-channel and multi-dimensional customer service system. During the Reporting Period, the industrial research institute of the Company continued to build an ecosystem of production, learning, research, investment and financial integration, empowered the development of various business segments, provided research support for policy formulation and industrial planning of government departments, and explored the establishment of industrial incubation and transformation cooperation mechanism with key scientific research universities to play a role as a bridge of “technology-finance-industry.The outstanding research capacity of the Company enjoys a high reputation in the industry and received numerous honors. The Company has received the New Fortune Domestic Best Research Teams and the New Fortune Most Influential Research Institution  for consecutive years from 2017 to 2023, and Top 5 Golden Bull Research Institution  award by China Securities Industry Analyst Golden Bull Award  for consecutive years. Meanwhile, it ranked in the forefront in the selection of Sell-side Analyst Crystal Ball Award , Best Analyst of Shanghai Securities News, the Golden Kirin  Best Analyst of Sina Finance and the Gold Analysts of the 21st Century .Continuous Improvement of Investment Banking Business with Outstanding FunctionalitiesGuided by customer demand, the Company has built an investment banking service system with a full business chain throughout the life cycle. During the Reporting Period, the Company actively implemented the national strategies and regulatory policies by adhering to the fundamental purpose of serving the real economy with finance and giving priority to functionality; focused on serving the development of new productive forces and national strategic emerging industries by deeply exploring “specialized, sophisticated, distinctive and innovative” enterprises and effectively fulfilled its responsibility as a “gatekeeper” in the capital market.In respect of domestic equity financing, as of the end of June 2024, the Company sponsored 43 companies listed on the NEEQ as the lead brokerage, of which 76.74% were “specialized, sophisticated, distinctive and innovative” enterprises. In respect of overseas equity financing, the Company completed two Hong Kong IPO projects including one IPO project as a sponsor with an issue size of HK$1.046 billion, ranking third in the market; completed two refinancing projects with an underwritten amount of HK$4.881 billion; and its equity financing business in Hong Kong ranked third among Chinese-based securities companies in terms of the total issuance size of IPOs and refinancing projects equally distributed among all underwriters, according to the statistics of Dealogic.In respect of bond and financing business, the Company attached great importance to serving national strategies and facilitated technological innovation enterprises to develop new productive forces; steadily enhanced its market position through leveraging the Group’s synergistic advantages, consistently expanding key regions, strengthening internal assessment mechanism and other measures, on the basis of a strict control of business development risk; and actively practices ESG to promote the green and lowcarbon development through bond and financing business. During the Reporting Period, the Company acted as the lead underwriter for 293 tranches of bonds, representing a year-on-year increase of 70.35%, with a lead underwritten amount of RMB152.428 billion, representing a year-on-year increase of 64.63%; acted as the lead underwriter for 52 tranches of various science and technology innovation bonds with an underwritten amount of RMB19.128 billion; and acted as the lead underwriter for 4 tranches of various low-carbon transformation and green bonds with an underwritten amount of RMB1.088 billion. In respect of Chinese offshore bond business, 33 bonds were issued with an underwritten amount of US$5.617 billion.In respect of financial advisory business, centered around the guidance of national industrial policies, financial policies and regional development policies, the Company practiced the business model of “One Guangfa” by holding a forum on merger and acquisition of new productive forces and building a merger and acquisition business ecosystem to provide customers with multi-level and all-round comprehensive services, promoting the orderly circulation of assets and capital. During the Reporting Period, the Company completed two projects in major asset restructuring and financial advisory business that had industry and regional influence, involving a total transaction amount of approximately RMB12.851 billion; and completed one overseas equity transaction, involving a transaction amount of approximately HK$1.098 billion. Two transactions in which the Company acted as buyer’s financial advisor were awarded the 2023-2024 Top Ten Domestic M&A Golden Whistle Award.In the future, GF Securities will continuously commit to its corporate values of “inquisitiveness and integrity” and carry forward its excellent cultural genes of an “army of doctors”, with knowledge as the guarantee and professionalism as the cornerstone, continue to deepen and consolidate the Company 's outstanding location advantage  in the Guangdong-Hong Kong-Macao Greater Bay Area and other places, deploy long-term strategies to well develop business with higher standard, accelerate high-quality development and contribute to serving the real economy. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Legend Holdings Corporation (“Legend Holdings” or the “Company”, Stock Code: 3396. HK) announces the unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2024 (the “Reporting Period”). In the first half of 2024, adhering to high-quality development driven by technological innovation, Legend Holdings prioritized stability while pursuing progress, responded to changes in macro factors, strived to develop new quality productive forces, and the Company’s core competitiveness was steadily improved. During the Reporting Period, the Company recorded revenue of RMB233.4 billion, representing a 16% year-on-year increase, with net profit increasing to RMB2.805 billion. The net profit attributable to equity holders of the Company was RMB286 million, and this year-on-year decrease recorded was primarily due to the increasing complexity and uncertainty of global economy, which had impacts on profits contributed by diversified-industries operation segment as well as the investment business of industrial incubations and investments segment.During the Reporting Period, Legend Holdings continued to drive industrial innovation through sci-tech innovation, emphasizing new quality productive forces as a key focus for the enterprise’s high-quality development, expanding its presence in frontier industries such as artificial intelligence, biopharmaceuticals, advanced materials and new energy, while exploring emerging frontiers and achieving positive outcomes in building up modernized industrial system. The Company has been committed to increasing its investment in technology development and innovation, with accumulated R&D investments increasing 3.4% to RMB7.3 billion. Lenovo Group, a subsidiary of Legend Holdings, achieved milestone breakthroughs in strategic products, including the launch of the first AI PCs worldwide and several AI servers. Meanwhile, the Legend Holdings Family Group has stepped up developments in frontier industries such as advanced materials, innovative drugs, biomanufacturing, and commercial space. Legend Holdings has also made forward-looking investments, making early moves in new sectors such as quantum technology and life sciences, which are expected to become the growth drivers for new quality productive forces. During the Reporting Period, Legend Holdings has invested in nearly 40 technology projects, and to date, the Company has invested in a total of 120 national specialized and innovative “little giant” enterprises, maintaining an industry-leading position.Legend Holdings has always been committed to serving national strategic needs and actively promoting the high-quality development of the manufacturing industry chain. By advancing new industrialization and boosting China’s strategic strength in manufacturing, and digital development, Legend Holdings has promoted the intelligent transformation and upgrading of China’s manufacturing industry. Currently, 90% of China’s top 500 manufacturers, over 1,000 leading manufacturing enterprises, and more than 2,000 growth manufacturing enterprises have received support from the Legend Holdings Family Group. Meanwhile, funds under the management of Legend Holdings have invested over RMB20 billion in the manufacturing sector, promoting the listing of dozens of manufacturing enterprises and fostering about 20 niche-sector leaders in the industry. As the world’s leading AI full-stack product portfolio and solution service provider, Legend Holdings has intensified its efforts to expand its footprint in AI and promote AI applications and built a vibrant AI+ application ecosystem with cumulative investments in over 250 AI-related companies. Meanwhile, Legend Holdings has actively promoted the industrialization of digital sectors and digital transformation of various industries. This includes supporting the proactive construction of digital infrastructure, and building a nationwide integrated computing power network to advance the deep integration of the digital economy with the real economy.Legend Holdings has always insisted on integrating the green concept into its high-quality development and actively fulfilled its social responsibilities. Lenovo Group was the first domestic high-tech manufacturer to pass the Science Based Targets initiative (SBTi) net-zero target validation, and its MSCI ESG rating remains at AAA, the highest rating in this assessment. A number of green industrial projects newly laid out by Levima Advanced Materials were completed in the first half of the year, and multiple projects are scheduled to be completed and put into production in 2025. ZQET Group is expanding in the photovoltaic industry. It has invested in a 20GW N-type high-efficiency solar cell smart manufacturing project, with the first phase already in operation and its core products ranking among the top tier of the industry. Meanwhile, Legend Holdings focuses on systematic planning and long-term investment in public welfare areas such as “rural revitalization”, “innovative technology” and “promoting righteousness”, and has been keeping contributing Legend's value to the society.In the face of challenges and opportunities, Legend Holdings will continue to deepen the high-quality development led by scientific and technological innovation. While strengthening its industrial foundation and optimizing the resource allocation, the Company will expand its presence in frontier areas, cultivate emerging and future industries, further focus on new quality productive forces, and build its new core competitiveness. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com)  Beijing Tong Ren Tang Chinese Medicine Company Limited (“Tong Ren Tang Chinese Medicine” or the “Company”, Stock code: 3613.HK) is pleased to announce the unaudited results of the Company and its subsidiaries (collectively referred to as the “Group”) for the six months ended 30 June 2024 (the “Period”).In the first half of 2024, facing challenges such as the sustained strength of the Hong Kong dollar, changing consumption patterns, and a sluggish retail industry in Hong Kong, China and Macau, China regions, the Group responded proactively and made simultaneous efforts from multiple dimensions of products, marketing, research and development, and production. This ensured the stable operation of its business and the continued consolidation of its market-leading position. During the Period, the Group achieved revenue of HK$ 664.5 million, net profit of HK$ 240.3 million, and profit attributable to owners of HK$ 219.8 million, with earnings per share of HK$ 0.26.By market segment, during the Period, the Group further enriched its product matrix and optimized its retail market layout. The Hong Kong, China market achieved revenue of HK$333.8 million, with 30 retail terminals, a net increase of 3 terminals compared with the previous year. In the markets outside Mainland China (excluding Hong Kong, China,), the Group accelerated its brand market expansion and steadily promoted its internationalization, achieving revenue of HK$214.4 million. In addition, the Group achieved revenue of HK$116.3 million in Mainland China market.Sufficient momentum from technological innovation, new breakthroughs in production and R&DThe development of science and technology has provided new technical support and growth strategies for the advancement of traditional Chinese medicine (“TCM”). During the Period, the Group leveraged technological innovation as a driving force, empowering intelligent upgrades in production and enhancing product excellence and innovation. This has helped accumulate new momentum for future growth and supported the inheritance and innovation of TCM.Product quality is the lifeline of an enterprise. At the production level, the Group’s production and R&D base in Tai Po consistently upholds stringent standards and rigorous procedural controls. The Group has successfully secured Hong Kong, China’s GMP and ISO22000 certifications, with its product quality has been recognized. Additionally, to further enhance the cost competitiveness of its products, the Group has intensified efforts in revamping and upgrading its production layout. By increasing mechanization and automation, the Gorup has effectively reduced production costs and boosted productivity, thereby ensuring consistent product availability in the market.In terms of products, the Group intensifies its R&D efforts, actively diversifying its product matrix and expediting the translation of scientific research outcomes. During the Period, the Group completed the production of a number of new registered proprietary Chinese medicines and health food products, including Guizhi Fuling Wan , Lingzhi Turmeric Compound Blood-supplementing and Nerve-calming Capsules , Wolfberry Coffee Mix , Red Ginseng Coffee Mix  and Sporoderm-broken Ganoderma Lucidum Spores Chocolate . The Group also plans to commence the production of Qiyao Pills ) and Jinshui Liujun Jian Granules. In April this year, the Group’s self-developed product, Danggui Buxue Keli, were awarded the Certificate of Registration of Proprietary Chinese Medicines (HKC-18604) issued by the Chinese Medicine Council of Hong Kong, China, further enriching the Group’s product portfolio. In May this year, the Group’s invention patent (Patent Number: ZL 2023 1 1206874.8) for “a freckle-removing and whitening product along with its preparation method and uses was successfully granted by China National Intellectual Property Administration and has been applied to Ageing-Defying Collection of the Tong Ren Tang’s Chinese anti-aging NMN series.In addition to preserving and advancing TCM services, the Group is also expanding into new health concept areas. During the Period, the Group entered into a Memorandum of Understanding with Deer Industry New Zealand to promote innovative health-functional deer food products, assisting both parties in collaborative development, registration and marketing efforts. The Group will give full play to strengths in both its proprietary brand and Chinese medicine, combined with the resource advantages provided by New Zealand, the origin of deer velvet, to accelerate the R&D of New Zealand deer products and the deployment of the industrial chain configuration, and continue to expand into new health domains.Moving forward, the Group will continue to strengthen its cooperation with internationally renowned institutions and research organizations such as the University of Hong Kong, Hong Kong Baptist University and the University of California, to conduct research on the safety and mechanism of key products such as Tong Ren Tang’s Angong Niuhuang Wan , Ganoderma Lucidum-related products and Tong Ren Niu Huang Qing Xin Wan, in order to further expand its scientific research results, and to provide a reliable scientific basis for the entry of its products into the mainstream markets overseas in the future. The Group adheres to the highest standards of superior, pure and genuine traditional Chinese medicinal materials, and brings together the essence of the intangible cultural heritage culture and exquisite craftsmanship, as well as strict and meticulous production to fully embody the Group’s motto: “Never cut corners on labour and quality, no matter how complex the process or how costly the materials”. This philosophy not only enhances the health value delivered to customers but also provides the Group with a stronger growth momentum.Orderly market expansion and diversified marketing to strengthen brand effectIn terms of market expansion, on the one hand, the Group has continuously introduced new products to consolidate and expand its market share. During the Period, the Group launched new products, including the Tong Ren Tang’s Chinese anti-aging NMN series – the Youth Prime Collection  and the Age-Defying Collection, the Guizhi Fuling Wan , and Wood Lok Medicated Oil , broadening its product range. At the same time, the Group further expanded its retail presence in Hong Kong, China by opening three new retail outlets in North Point, Mong Kok, and West Kowloon. The North Point and West Kowloon stores also offer Chinese medical consultation and treatments to reach a wider customer base.In terms of product marketing, the Group has intensified its marketing efforts to increase product recognition. Specifically targeting the “major variety” products, such as Tong Ren Tang Angong Niuhuang Wan and Sporoderm-broken Ganoderma Lucidum Spores Powder Capsule and Tong Ren Niu Huang Qing Xin Wan, the Group promoted and advertised the brand and products through an omni-channel approach, integrating special festivals and themes to create consumer hotspots. Moreover, the Group has also advanced the development of both online and offline channels, continuously expanding its sales channels to meet the demands of post-pandemic era business models.In terms of brand promotion, the Group capitalized on its participation in major events, significantly enhancing its promotional efforts and accelerating the brand market expansion. During the Period, serving as a critical portal for Beijing Tong Ren Tang’s international development, the Group participated in the 2024 Wuzhen Health Conference, showcasing its flagship products and a variety of new products. In implementing the “Belt and Road” initiative, the Group leads time-honored brands venture into the world and integrates into the international arena. By adopting the “bring in” and “go global” strategy, the Group is promoting the rich and profound TCM culture, further disseminates Chinese health wisdom globally to benefit more people.Additionally, the Group has enhanced its brand image and influence through public welfare activities. The Group has actively encouraged its overseas retail outlets that offer Chinese medical consultations and treatments to provide charity Chinese medicine clinic services. This initiative embodies the Group’s philosophy of “introducing medicine through treatments” and supports its brand development. In Hong Kong, China, the Group has fully supported and participated in public welfare activities, demonstrating to society and the public the Group’s corporate spirit of “Nurturing kindness and virtue, preserving tranquility and wellness ”. Through its services and products, the Group is dedicated to deeply embedding the Tong Ren Tang brand, products and Chinese medical consultation and treatments services into the community, spreading the culture of Tong Ren Tang while encouraging a healthy lifestyle among community residents.Future ProspectsWith the ongoing economic and social development, an intensifying aging population trend, and the increasing health awareness among residents, the pharmaceutical consumption market is expected to expand continuously. TCM, as a crucial sector of the pharmaceutical industry, continues to hold significant potential for growth in the global market.In the future, the Group will continue to strengthen R&D efforts and expand its proprietary product matrix, including products such as Ganoderma Lucidum series and anti-aging series, to create diversified growth engines and drive the realization of high-quality developmental transformation within the Group. At the same time, the Group will focus on business development by enhancing its new retail layout, accelerating the introduction of new products, continuously advancing the registration of Tong Ren Tang’s key products in Vietnam, innovating business models, and reinforcing its core competitive advantages. By leveraging the development of new quality productive forces as its engine, the Group strives to achieve sustained growth in its business scale. Copyright 2024 ACN Newswire via SeaPRwire.com.